Tiziana's Foralumab Shows Positive Preclinical Data for Long COVID Neuroinflammation
Summary
Tiziana Life Sciences announced the publication of positive preclinical data for its lead candidate, intranasal foralumab, demonstrating its potential to attenuate Long COVID neuroinflammation and improve cognitive function. The data, published on bioRxiv by independent academic collaborators, showed the anti-CD3 antibody reduced neuroinflammation, boosted regulatory T cells, and restored neurogenesis in a mouse model. This news, while preclinical and from a preprint server, is a material positive development for a small-cap biotech, expanding the potential indications for their lead asset. It provides further validation for foralumab, which is already in clinical development for other neuroinflammatory conditions. Investors will now watch for further clinical development plans for foralumab in Long COVID, including potential IND filings and the initiation of human trials.
At the time of this announcement, TLSA was trading at $1.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $158.1M. The 52-week trading range was $0.76 to $2.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.